Identification of somatostatin receptor type 5 gene polymorphisms associated with acromegaly

European Journal of Endocrinology

Volumn 165, Issue 4, 2011, Pages 517-525

  Ciganoka, Darja ^a   Balcere, Inga ^b   Kapa, Ivo ^a   Peculis, Raitis ^a   Valtere, Andra ^d   Nikitina Zake, Liene ^a   Lase, Ieva ^b   Schiöth, Helgi B ^e   Pirags, Valdis ^a,b,c   Klovins, Janis ^a,e  

^a LATVIAN BIOMEDICAL RESEARCH AND STUDY CENTRE   (Latvia)

^b PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^c UNIVERSITY OF LATVIA   (Latvia)

^d RIGA EAST UNIVERSITY HOSPITAL   (Latvia)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; DNA; GROWTH HORMONE; OCTREOTIDE; SOMATOSTATIN RECEPTOR 5; SOMATULINE AUTOGEL; UNCLASSIFIED DRUG;

ACROMEGALY; ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ENDOCRINE SURGERY; FEMALE; GENE FREQUENCY; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOME SIZE; HAPLOTYPE; HIGH RISK POPULATION; HORMONE SYNTHESIS; HUMAN; HYPOPHYSIS ADENOMA; MALE; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; RECEPTOR GENE; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATOSTATIN RECEPTOR 5 GENE; TUMOR GROWTH;

ACROMEGALY; AGED; ALLELES; DATABASES, GENETIC; DNA; FEMALE; HAPLOTYPES; HORMONES; HUMANS; LATVIA; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, SOMATOSTATIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 80053506538     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0416     Document Type: Article

References (43)

1. Melmed S. Acromegaly pathogenesis and treatment. Journal of Clinical Investigation 2009 119 3189-3202. (doi:10.1172/JCI39375)
2. Bengtsson BA, Eden S, Ernest I, Oden A & Sjogren B. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Medica Scandinavica 1988 223 327-335. (doi:10.1111/j.0954-6820. 1988.tb15881.x)
3. Hoyer D, Bell GI, Berelowitz M, Epelbaum J, Feniuk W, Humphrey PP, O'Carroll AM, Patel YC, Schonbrunn A, Taylor JE & Reisine T. Classification and nomenclature of somatostatin receptors. Trends in Pharmacological Sciences 1995 16 86-88. (doi:10.1016/S0165-6147(00)88988-9)
4. Reisine T & Bell GI. Molecular biology of somatostatin receptors. Endocrine Reviews 1995 16 427-442. (doi:10.1016/0166-2236(93)90050-V)
5. Taboada GF, Luque RM, Neto LV, Machado Ede O, Sbaffi BC, Domingues RC, Marcondes JB, Chimelli LM, Fontes R, Niemeyer P, De Carvalho DP, Kineman RD & Gadelha MR. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. European Journal of Endocrinology 2008 158 295-303. (doi:10.1530/EJE-07-0562)
6. Lamberts SW, Krenning EP & Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrine Reviews 1991 12 450-482. (doi:10.1210/edrv-12-4-450)
7. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S & Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism 2005 90 4465-4473. (doi:10.1210/jc.2005-0260)
8. Bronstein MD. Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome. Frontiers of Hormone Research 2006 35 129-134. (doi:10.1159/00009-4315)
9. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K & Giustina A. Guidelines for acromegaly management: an update. Journal of Clinical Endocrinology and Metabolism 2009 94 1509-1517. (doi:10.1210/jc.2008-2421)
10. Colao A, Auriemma RS, Lombardi G & Pivonello R. Resistance to somatostatin analogs in acromegaly. Endocrine Reviews 2011 32 247-271. (doi:10.1210/er.2010-0002)
11. Lania A, Mantovani G & Spada A. Genetic abnormalities of somatostatin receptors in pituitary tumors. Molecular and Cellular Endocrinology 2008 286 180-186. (doi:10.1016/j.mce.2007.08.013)
12. Landis CA, Harsh G, Lyons J, Davis RL, McCormick F & Bourne HR. Clinical characteristics of acromegalic patients whose pituitary tumors contain mutant Gs protein. Journal of Clinical Endocrinology and Metabolism 1990 71 1416-1420. (doi:10.1210/jcem-71-6-1416)
13. Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen K, Ebeling TM, Salmela PI, Paschke R, Gundogdu S, De Menis E, Makinen MJ, Launonen V, Karhu A & Aaltonen LA. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006 312 1228-1230. (doi:10.1126/science.1126100)
14. Cazabat L, Guillaud-Bataille M, Bertherat J & Raffin-Sanson ML. Mutations of the gene for the aryl hydrocarbon receptorinteracting protein in pituitary adenomas. Hormone Research 2009 71 132-141. (doi:10.1159/000197869)
15. Daly AF, Tichomirowa MA, Petrossians P, Heliovaara E, Jaffrain-Rea ML, Barlier A, Naves LA, Ebeling T, Karhu A, Raappana A, Cazabat L, De Menis E, Montanana CF, Raverot G, Weil RJ, Sane T, Maiter D, Neggers S, Yaneva M, Tabarin A, Verrua E, Eloranta E, Murat A, Vierimaa O, Salmela PI, Emy P, Toledo RA, Sabate MI, Villa C, Popelier M, Salvatori R, Jennings J, Longas AF, Labarta Aizpun JI, Georgitsi M, Paschke R, Ronchi C, Valimaki M, Saloranta C, De Herder W, Cozzi R, Guitelman M, Magri F, Lagonigro MS, Halaby G, Corman V, Hagelstein MT, Vanbellinghen JF, Barra GB, Gimenez-Roqueplo AP, Cameron FJ, Borson-Chazot F, Holdaway I, Toledo SP, Stalla GK, Spada A, Zacharieva S, Bertherat J, Brue T, Bours V, Chanson P, AaltonenLA& Beckers A. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. Journal of Clinical Endocrinology and Metabolism 2010 95 E373-E383. (doi:10.1210/jc.2009-2556)
16. Filopanti M, Ronchi C, Ballare E, Bondioni S, Lania AG, Losa M, Gelmini S, Peri A, Orlando C, Beck-Peccoz P & Spada A. Analysis of somatostatin receptors 2 and 5 polymorphisms in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2005 90 4824-4828. (doi:10.1210/jc.2005-0132)
17. Ballare E, Persani L, Lania AG, Filopanti M, Giammona E, Corbetta S, Mantovani S, Arosio M, Beck-Peccoz P, Faglia G & Spada A. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. Journal of Clinical Endocrinology and Metabolism 2001 86 3809-3814. (doi:10.1210/jc.86.8.3809)
18. Corbetta S, Ballare E, Mantovani G, Lania A, Losa M, Di Blasio AM & Spada A. Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary adenomas: analysis of gene sequence and mRNA expression. European Journal of Clinical Investigation 2001 31 208-214. (doi:10.1046/j.1365-2362.2001.00786.x)
19. Petersenn S, Heyens M, Ludecke DK, Beil FU & Schulte HM. Absence of somatostatin receptor type 2A mutations and gip oncogene in pituitary somatotroph adenomas. Clinical Endocrinology 2000 52 35-42. (doi:10.1046/j.1365- 2265.2000.00880.x)
20. van der Hoek J, Lamberts SW & Hofland LJ. The somatostatin receptor subtype 5 in neuroendocrine tumours. Expert Opinion on Investigational Drugs 2010 19 385-399. (doi:10.1517/13543781003604710)
21. Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, Von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V,Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante- Rivard C, Stewart AF & Birkett N. Strengthening the reporting of genetic association studies (STREGA): an extension of the strengthening the reporting of observational studies in epidemiology (STROBE) statement. Journal of Clinical Epidemiology 2009 62 597-608. (doi:10.1016/j.jclinepi.2008.12.004)
22. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, De Bakker PI, Daly MJ & Sham PC. PLINK: a tool set for whole-genome association and population-based linkage analyses. American Journal of Human Genetics 2007 81 559-575. (doi:10.1086/519795)
23. Wigginton JE, Cutler DJ & Abecasis GR. A note on exact tests of Hardy-Weinberg equilibrium. American Journal of Human Genetics 2005 76 887-893. (doi:10.1086/429864)
24. Nyegaard M, Borglum AD, Bruun TG, Collier DA, Russ C, Mors O, Ewald H & Kruse TA. Novel polymorphisms in the somatostatin receptor 5 (SSTR5) gene associated with bipolar affective disorder. Molecular Psychiatry 20027745-754. (doi:10.1038/sj.mp.4001049)
25. Lauritsen MB, Nyegaard M, Betancur C, Colineaux C, Josiassen TL, Kruse TA, Leboyer M & Ewald H. Analysis of transmission of novel polymorphisms in the somatostatin receptor 5 (SSTR5) gene in patients with autism. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 2003 121B 100-104. (doi:10.1002/ajmg.b.20050)
26. Li D, Tanaka M, Brunicardi FC, Fisher WE, Gibbs RA & Gingras MC. Association between somatostatin receptor 5 gene polymorphisms and pancreatic cancer risk and survival. Cancer 2011 117 2863-2872. (doi:10.1002/cncr.25858)
27. Canzian F, McKay JD, Cleveland RJ, Dossus L, Biessy C, Boillot C, Rinaldi S, Llewellyn M, Chajes V, Clavel-Chapelon F, Tehard B, Chang-Claude J, Linseisen J, Lahmann PH, Pischon T, Trichopoulos D, Trichopoulou A, Zilis D, Palli D, Tumino R, Vineis P, Berrino F, Bueno-de-Mesquita HB, van Gils CH, Peeters PH, Pera G, Barricarte A, Chirlaque MD, Quiros JR, Larranaga N, Martinez-Garcia C, Allen NE, Key TJ, Bingham SA, Khaw KT, Slimani N, Norat T, Riboli E & Kaaks R. Genetic variation in the growth hormone synthesis pathway in relation to circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3, and breast cancer risk: results from the European prospective investigation into cancer and nutrition study. Cancer Epidemiology, Biomarkers & Prevention 2005 14 2316-2325. (doi:10.1158/1055-9965.EPI-04-0874)
28. Gu F, Schumacher FR, Canzian F, Allen NE, Albanes D, Berg CD, Berndt SI, Boeing H, Bueno-de-Mesquita HB, Buring JE, Chabbert- Buffet N, Chanock SJ, Clavel-Chapelon F, Dumeaux V, Gaziano JM, Giovannucci EL, Haiman CA, Hankinson SE, Hayes RB, Henderson BE, Hunter DJ, Hoover RN, Johansson M, Key TJ, Khaw KT, Kolonel LN, Lagiou P, Lee IM, LeMarchand L, Lund E, Ma J, Onland-Moret NC, Overvad K, Rodriguez L, Sacerdote C, Sanchez MJ, Stampfer MJ, Stattin P, Stram DO, Thomas G, Thun MJ, Tjonneland A, Trichopoulos D, Tumino R, Virtamo J, Weinstein SJ, Willett WC, Yeager M, Zhang SM, Kaaks R, Riboli E, Ziegler RG & Kraft P. Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer. Cancer Epidemiology, Biomarkers & Prevention 2010 19 2877-2887. (doi:10.1158/1055-9965.EPI-10-0507)
29. Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler MD, Moreau JP, Enjalbert A & Jaquet P. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. Journal of Clinical Endocrinology and Metabolism 2001 86 140-145. (doi:10.1210/jc.86.1.140)
30. Hofland LJ, van der Hoek J, van Koetsveld PM, De Herder WW, Waaijers M, Sprij-Mooij D, Bruns C,Weckbecker G, Feelders R, van der Lely AJ, Beckers A & Lamberts SW. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. Journal of Clinical Endocrinology and Metabolism 2004 89 1577-1585. (doi:10.1210/jc.2003-031344)
31. Plockinger U, Albrecht S, Mawrin C, Saeger W, Buchfelder M, Petersenn S & Schulz S. Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas. Journal of Clinical Endocrinology and Metabolism 2008 93 1203-1210. (doi:10.1210/jc.2007-1986)
32. Park C, Yang I, Woo J, Kim S, Kim J, Kim Y, Sohn S, Kim E, Lee M, Park H, Jung J & Park S. Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide. Endocrine Journal 2004 51 227-236. (doi:10.1507/endocrj.51.227)
33. Taboada GF, Luque RM, Bastos W, Guimaraes RF, Marcondes JB, Chimelli LM, Fontes R, Mata PJ, Filho PN, Carvalho DP, Kineman RD & Gadelha MR. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. European Journal of Endocrinology 2007 156 65-74. (doi:10.1530/eje.1.02313)
34. Tulipano G, Bonfanti C, Milani G, Billeci B, Bollati A, Cozzi R, Maira G, MurphyWA, Poiesi C, Turazzi S & Giustina A. Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro. Neuroendocrinology 2001 73 344-351. (doi:10.1159/000054651)
35. Jaquet P, Saveanu A, Gunz G, Fina F, Zamora AJ, Grino M, Culler MD, Moreau JP, Enjalbert A & Ouafik LH. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. Journal of Clinical Endocrinology and Metabolism 2000 85 781-792. (doi:10.1210/jc.85.2.781)
36. Ren SG, Taylor J, Dong J, Yu R, Culler MD & Melmed S. Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. Journal of Clinical Endocrinology and Metabolism 2003 88 4239-4245. (doi:10.1210/jc.2003-030303)
37. Duran-Prado M, Gahete MD, Martinez-Fuentes AJ, Luque RM, Quintero A, Webb SM, Benito-Lopez P, Leal A, Schulz S, Gracia-Navarro F, Malagon MM & Castano JP. Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. Journal of Clinical Endocrinology and Metabolism 2009 94 2634-2643. (doi:10.1210/jc.2008-2564)
38. Duran-Prado M, Saveanu A, Luque RM, Gahete MD, Gracia-Navarro F, Jaquet P, Dufour H, Malagon MM, Culler MD, Barlier A & Castano JP. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs. Journal of Clinical Endocrinology and Metabolism 2010 95 2497-2502. (doi:10.1210/jc.2009-2247)
39. Duran-Prado M, Malagon MM, Gracia-Navarro F & Castano JP. Dimerization of G protein-coupled receptors: new avenues for somatostatin receptor signalling, control and functioning. Molecular and Cellular Endocrinology 2008 286 63-68. (doi:10.1016/j.mce.2007.12.006)
40. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC & Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000 288 154-157. (doi:10.1126/science. 288.5463.154)
41. Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC & Patel YC. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. Journal of Biological Chemistry 2000 275 7862-7869. (doi:10.1074/jbc.275.11.7862)
42. Sharma K, Patel YC & Srikant CB. C-terminal region of human somatostatin receptor 5 is required for induction of Rb and G1 cell cycle arrest. Molecular Endocrinology 1999 13 82-90. (doi:10.1210/me.13.1.82)
43. Zhou G, Gingras MC, Liu SH, Li D, Li Z, Catania RL, Stehling KM, Li M, Paganelli G, Gibbs RA, Demayo FJ, FisherWE& Brunicardi FC. The hypofunctional effect of P335L single nucleotide polymorphism on SSTR5 function. World Journal of Surgery 2011 35 1715-1724. (doi:10.1007/s00268-010-0939-9)